Newsfeeds - Spark Newswire

2 minute read

MediWound Announces $27.5M Registered Direct Offering Of 1,964,286 Ordinary Shares Priced At-The-Market

Today, 1:24 PM

MediWound Ltd. (NASDAQ:MDWD) (the "Company"), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has

MDWD

2 minute read

Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday

By Lisa Levin

Today, 1:24 PM

UBS cut Microsoft Corporation (NASDAQ: MSFT) price target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market trading.

1 minute read

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $23

By Benzinga Newsdesk

Today, 1:24 PM

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and raises the price target from $5.5 to $23.

MDWD

1 minute read

Cowen & Co. Maintains Outperform on MediWound, Adjusts Price Target to $25 – 1-for-7 Reverse Stock Split

By Benzinga Newsdesk

Today, 1:24 PM

Cowen & Co. analyst Joshua Jennings maintains MediWound (NASDAQ:MDWD) with a Outperform, adjusts price target to $25 - 1-for-7 reverse stock split.

MDWD

1 minute read

FDA Approves MediWound’s NexoBrid For Burn Treatment

By Vandana Singh

Today, 1:24 PM

The FDA has approved MediWound Ltd’s (NASDAQ:MDWD) NexoBrid (anacaulase-bcdb) to remove eschar in adults with deep partial-thickness and/or full-thickness thermal burns.…

MDWD

1 minute read

FDA
News

FDA Site Shows Approval For MediWound’s NexoBrid

By Benzinga Newsdesk

Today, 1:24 PM

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761192

MDWD

5 minute read

Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors

By Shanthi Rexaline

Today, 1:24 PM

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

BGNE

1 minute read

Oppenheimer Maintains Outperform on MediWound, Adjusts Price Target to $63 – 1-for-7 Reverse Stock Split

By Benzinga Newsdesk

Today, 1:24 PM

Oppenheimer analyst Francois Brisebois maintains MediWound (NASDAQ:MDWD) with a Outperform, adjusts price target to $63 - 1-for-7 reverse stock split.

MDWD

11 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 1:24 PM

Tuesday's session saw 167 companies set new 52-week lows.

ACHL

2 minute read

MediWound Announces A 1-For-7 Reverse Share Split Effective December 20

By Benzinga Newsdesk

Today, 1:24 PM

MediWound Ltd. (NASDAQ:MDWD) ("MediWound" or the "Company"), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today

MDWD